19,179 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Quantitative Investment Management LLC

Quantitative Investment Management LLC purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 19,179 shares of the biotechnology company’s stock, valued at approximately $1,593,000.

A number of other large investors also recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in shares of Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 2,444 shares during the period. Amundi purchased a new position in shares of Corcept Therapeutics during the 1st quarter valued at approximately $450,000. NewEdge Advisors LLC acquired a new position in shares of Corcept Therapeutics in the 1st quarter valued at $518,000. Envestnet Asset Management Inc. boosted its holdings in Corcept Therapeutics by 22.3% during the second quarter. Envestnet Asset Management Inc. now owns 38,847 shares of the biotechnology company’s stock worth $2,851,000 after buying an additional 7,077 shares in the last quarter. Finally, Bank of Montreal Can boosted its holdings in Corcept Therapeutics by 2.1% during the second quarter. Bank of Montreal Can now owns 17,351 shares of the biotechnology company’s stock worth $1,274,000 after buying an additional 353 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Stock Performance

CORT opened at $32.39 on Friday. The firm’s fifty day simple moving average is $37.87 and its two-hundred day simple moving average is $63.44. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $117.33. The company has a market cap of $3.45 billion, a price-to-earnings ratio of 39.50 and a beta of 0.29. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.26 EPS. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Corcept Therapeutics news, insider William Guyer sold 8,233 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67. Following the completion of the transaction, the insider owned 2,231 shares of the company’s stock, valued at $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 48,233 shares of company stock worth $1,817,306. 20.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. HC Wainwright lowered their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. UBS Group assumed coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Canaccord Genuity Group lifted their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Finally, Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $77.17.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: H.C. Wainwright cut its price target on CORT from $67 to $60 but kept a Buy rating — a mixed signal that preserves analyst support while lowering upside expectations. H.C. Wainwright Cuts Price Target
• Neutral Sentiment: Short‑interest reporting in recent feeds shows anomalous/zero values (0 shares, NaN) and thus provides no clear indication of a coordinated short trade; treat these figures with caution until cleaner data is available.
• Negative Sentiment: Rosen Law Firm is soliciting Corcept investors to join the securities class action and warns of an April 21, 2026 lead‑plaintiff deadline — amplifying legal risk and potential settlement exposure. Rosen Law Firm Notice
• Negative Sentiment: Hagens Berman and several other plaintiff firms (Pomerantz, Bernstein Liebhard, Levi & Korsinsky, Glancy, Schall, DJS, Johnson Fistel, Kaplan Fox, etc.) have notified/investigated investors about the same securities claim — the proliferation of firms increases publicity and the likelihood of litigation costs or settlement activity. Hagens Berman Alert
• Negative Sentiment: Pomerantz and other firms are similarly urging affected investors to contact them ahead of the April 21 deadline, keeping the story in the headlines and pressuring sentiment. Pomerantz Notice

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.